Literature DB >> 25586402

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.

Peter S Hendricks1, Christopher B Thorne2, C Brendan Clark3, David W Coombs2, Matthew W Johnson4.   

Abstract

Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA adult respondents pooled from the last five available years of the National Survey on Drug Use and Health (2008-2012) while controlling for a range of covariates. Lifetime classic psychedelic use was associated with a significantly reduced odds of past month psychological distress (weighted odds ratio (OR)=0.81 (0.72-0.91)), past year suicidal thinking (weighted OR=0.86 (0.78-0.94)), past year suicidal planning (weighted OR=0.71 (0.54-0.94)), and past year suicide attempt (weighted OR=0.64 (0.46-0.89)), whereas lifetime illicit use of other drugs was largely associated with an increased likelihood of these outcomes. These findings indicate that classic psychedelics may hold promise in the prevention of suicide, supporting the view that classic psychedelics' most highly restricted legal status should be reconsidered to facilitate scientific study, and suggesting that more extensive clinical research with classic psychedelics is warranted.
© The Author(s) 2015.

Entities:  

Keywords:  Psychedelic; hallucinogen; lysergic acid diethylamide; mental health; prevention; psilocybin; suicide

Mesh:

Substances:

Year:  2015        PMID: 25586402     DOI: 10.1177/0269881114565653

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  69 in total

Review 1.  Psychedelic medicine: a re-emerging therapeutic paradigm.

Authors:  Kenneth W Tupper; Evan Wood; Richard Yensen; Matthew W Johnson
Journal:  CMAJ       Date:  2015-09-08       Impact factor: 8.262

Review 2.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 3.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

4.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

Review 5.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

6.  LSD-induced entropic brain activity predicts subsequent personality change.

Authors:  A V Lebedev; M Kaelen; M Lövdén; J Nilsson; A Feilding; D J Nutt; R L Carhart-Harris
Journal:  Hum Brain Mapp       Date:  2016-05-06       Impact factor: 5.038

Review 7.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

8.  Psilocybin, psychological distress, and suicidality.

Authors:  Peter S Hendricks; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-09       Impact factor: 4.153

9.  Psychological Distress Behavioral Patterns Among Latinos: We Don't See Ourselves as Worthless.

Authors:  Armando Barragán; Ann-Marie Yamada; Tamika D Gilreath
Journal:  Community Ment Health J       Date:  2018-04-26

Review 10.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.